Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenoviridae Infections × 1-dodecylpyridoxal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 16 Fallopian Tube Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Breast Neoplasms 5 Multiple Myeloma 4 Stomach Neoplasms 2 Platinum-resistant Recurrent Ovarian Cancer 2 Melanoma 2 Lymphoma 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Recurrence 1 Peritoneal Neoplasms 1 Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Follicular 1 Hematologic Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Advanced Malignancies 1 Adenoviridae Infections 1

Interventions

Gemcitabine 2 Cell Count 2 valrubicin 1 tretazicar 1 pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 fludarabine 1 enadenotucirev 1 atezolizumab 1 Vaccines 1 Tumor Necrosis Factor-alpha 1 Radiotherapy 1 Oncolytic Virotherapy 1 Mitomycin 1 Interferons 1 Interferon-beta 1 Genetic Engineering 1 Endostatins 1 Capecitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271318 2025-11-03

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡